Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II Study of Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer (OPEB-01)

NCT04361370 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT04361370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04361370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II Study of Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer (OPEB-01)
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
October 28, 2020
Completion date
August 31, 2026
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-sensitive recurrent brca wild type ovarian cancer